Dodge & CoxALNY history

Issuer:
Alnylam Pharmaceuticals, Inc.
Quarters tracked:
40 (Q2 2016Q1 2026)
Current shares:
1,929,253
Current value:
$638.33M
Peak shares:
9,399,245 (Q1 2017)
Overall change:
-23%
QuarterSharesValue$/ShareShare ΔΔ%
Q1 20261,929,253$638.33M$330.87-35,162-2%
Q4 20251,964,415$781.15M$397.65-356,815-15%
Q3 20252,321,230$1.06B$456.00-875,866-27%
Q2 20253,197,096$1.04B$326.09-154,666-5%
Q1 20253,351,762$905.04M$270.02-188,500-5%
Q4 20243,540,262$833.06M$235.31-82,273-2%
Q3 20243,622,535$996.31M$275.03-157,650-4%
Q2 20243,780,185$918.59M$243.00-31,295-1%
Q1 20243,811,480$569.63M$149.45+137,170+4%
Q4 20233,674,310$703.30M$191.41-72,845-2%
Q3 20233,747,155$663.62M$177.10-42,370-1%
Q2 20233,789,525$719.78M$189.94-105,010-3%
Q1 20233,894,535$780.15M$200.32-696,247-15%
Q4 20224,590,782$1.09B$237.65-298,515-6%
Q3 20224,889,297$978.64M$200.16-369,659-7%
Q2 20225,258,956$767.02M$145.85-216,712-4%
Q1 20225,475,668$894.12M$163.29+44,600+1%
Q4 20215,431,068$921.00M$169.58+58,968+1%
Q3 20215,372,100$1.01B$188.81-41,901-1%
Q2 20215,414,001$917.78M$169.52+1,092,374+25%
Q1 20214,321,627$610.17M$141.19-318,286-7%
Q4 20204,639,913$603.05M$129.97-37,700-1%
Q3 20204,677,613$681.06M$145.60-26,058-1%
Q2 20204,703,671$696.66M$148.11-389,675-8%
Q1 20205,093,346$554.41M$108.85-157,975-3%
Q4 20195,251,321$604.79M$115.17-60,480-1%
Q3 20195,311,801$427.18M$80.42+70,300+1%
Q2 20195,241,501$380.32M$72.56+243,500+5%
Q1 20194,998,001$467.06M$93.45+307,750+7%
Q4 20184,690,251$341.97M$72.91+34,600+1%
Q3 20184,655,651$407.46M$87.52+9500%
Q2 20184,654,701$458.44M$98.49-38,140-1%
Q1 20184,692,841$558.92M$119.10-3,538,754-43%
Q4 20178,231,595$1.05B$127.05-909,900-10%
Q3 20179,141,495$1.07B$117.49-44,3250%
Q2 20179,185,820$732.66M$79.76-213,425-2%
Q1 20179,399,245$481.71M$51.25+194,295+2%
Q4 20169,204,950$344.63M$37.44+3,928,882+74%
Q3 20165,276,068$357.61M$67.78+2,759,399+110%
Q2 20162,516,669$139.65M$55.49NEW